The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.
Earnings season begins again, while big readouts loom for ALX and Fibrogen.
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.